Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform

Attovia Therapeutics announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. The funding will support building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody™ platform.